Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Citi
Dow
Argus Health
Teva
Chinese Patent Office
Chubb
US Department of Justice

Generated: February 20, 2019

DrugPatentWatch Database Preview

Ombitasvir; paritaprevir; ritonavir - Generic Drug Details

« Back to Dashboard

What are the generic sources for ombitasvir; paritaprevir; ritonavir and what is the scope of ombitasvir; paritaprevir; ritonavir freedom to operate?

Ombitasvir; paritaprevir; ritonavir is the generic ingredient in one branded drug marketed by Abbvie Inc and is included in one NDA. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ombitasvir; paritaprevir; ritonavir has three hundred and sixty patent family members in forty-five countries.

One supplier is listed for this compound.

Summary for ombitasvir; paritaprevir; ritonavir

US Patents and Regulatory Information for ombitasvir; paritaprevir; ritonavir

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie Inc TECHNIVIE ombitasvir; paritaprevir; ritonavir TABLET;ORAL 207931-001 Jul 24, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Abbvie Inc TECHNIVIE ombitasvir; paritaprevir; ritonavir TABLET;ORAL 207931-001 Jul 24, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Abbvie Inc TECHNIVIE ombitasvir; paritaprevir; ritonavir TABLET;ORAL 207931-001 Jul 24, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Abbvie Inc TECHNIVIE ombitasvir; paritaprevir; ritonavir TABLET;ORAL 207931-001 Jul 24, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Abbvie Inc TECHNIVIE ombitasvir; paritaprevir; ritonavir TABLET;ORAL 207931-001 Jul 24, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for ombitasvir; paritaprevir; ritonavir

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie Inc TECHNIVIE ombitasvir; paritaprevir; ritonavir TABLET;ORAL 207931-001 Jul 24, 2015 ➤ Try a Free Trial ➤ Try a Free Trial
Abbvie Inc TECHNIVIE ombitasvir; paritaprevir; ritonavir TABLET;ORAL 207931-001 Jul 24, 2015 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for ombitasvir; paritaprevir; ritonavir

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2017033 Lithuania ➤ Try a Free Trial PRODUCT NAME: PIBRENTASVIRAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/17/1213 20170726
0150016 00154 Estonia ➤ Try a Free Trial PRODUCT NAME: OMBITASVIIR;REG NO/DATE: EU/1/14/982 19.01.2015
C0016 France ➤ Try a Free Trial PRODUCT NAME: OMBITASVIR DANS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; REGISTRATION NO/DATE: EU/1/14/982 20150119
C0021 France ➤ Try a Free Trial PRODUCT NAME: PARITAPREVIR DANS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; REGISTRATION NO/DATE: EU/1/14/982 20150119
2015011 Lithuania ➤ Try a Free Trial PRODUCT NAME: PARITAPREVIRUM; REGISTRATION NO/DATE: EU/1/14.982 20150115
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Covington
Citi
McKinsey
Medtronic
Harvard Business School
Colorcon
Johnson and Johnson
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.